Stryker sells to the people who treat patients: doctors, hospitals and clinics, which it reaches mostly through its own sales teams. The United States is by far its largest market, with 75.7% of sales.
The business has two parts. The larger one makes surgical and emergency equipment, such as stretchers and defibrillators, along with devices for the brain and its blood vessels; in 2025 it brought in $15.6 billion. The smaller part is orthopaedics. It sold $9.5 billion of replacement joints, implants that mend broken bones, and the tools surgeons use to fit them.
A hospital that uses a Mako robot shows how the money comes in. The robot is an arm that guides the surgeon's cuts during a joint replacement, and the hospital pays for it once. Every patient, however, needs a new knee or hip, so each operation brings Stryker another implant sale. The robot began with knees. Stryker has since extended it to hips and is now bringing it to shoulders.
Stryker is still buying. In 2025 Stryker bought Inari, a maker of devices that treat blood clots in the veins. It then renamed its brain-vessel unit Vascular, so that one unit now holds both businesses. Vascular sales rose from $1.3 billion in 2024 to $2.0 billion in 2025. In our reading, a jump of that size in one year suggests that much of it came with Inari.
In May 2026 Stryker bought another maker of devices for blood vessels. Its recent deals have moved it steadily further into that field, while the robot keeps reaching new joints. By the company's own account, this is the direction it is taking, and it is getting there largely by buying.